IP Library Granted Patent US 12,060,585
Granted Patent B2
US 12,060,585 · App. 17/302,514 · Granted Aug 13, 2024

Expression of novel cell tags

Inventors: Rutul Shah (Germantown, MD); Peter Emtage (Germantown, MD); Ramya Yarlagadda (Germantown, MD)
Assignee: PRECIGEN, INC.
C12N9/12A61K35/17A61K39/3955A61P35/00C07K14/5443C07K14/70503C07K14/7051C07K14/70521C07K14/70578C07K14/70592C07K14/70596C07K14/71C07K16/2887C07K16/32C12Y207/10001A61K2039/505C07K2317/622C07K2317/732C07K2317/734C07K2319/00C07K2319/02C07K2319/03C07K2319/33
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,060,585
App. No.
17/302,514
Granted
Aug 13, 2024
Kind
B2
Abstract

Disclosed herein are polynucleotides encoding cell tags for use in immunotherapeutic applications, and systems comprising polynucleotide cell tags for regulating the activity of a cell. The compositions, methods and systems described herein provide tools for regulating activity of genetically engineered cells in a subject.

Claims (16)

1. A recombinant polypeptide comprising an amino acid sequence having at least 90% identity with the sequence of any one of SEQ ID NOs: 57, 73, 77, and 81;

wherein the recombinant polypeptide does not comprise an intracellular signaling domain.

2. The recombinant polypeptide of claim 1 , comprising an amino acid sequence having at least 90% identity with the sequence of SEQ ID NO: 57.

3. The recombinant polypeptide of claim 1 , comprising an amino acid sequence having at least 95% identity with the sequence of SEQ ID NO: 57.

4. The recombinant polypeptide of claim 1 , comprising an amino acid sequence having at least 99% identity with the sequence of SEQ ID NO: 57.

5. The recombinant polypeptide of claim 1 , further comprising a signal peptide.

6. The recombinant polypeptide of claim 5 , wherein the signal peptide is a GMCSFRα, Ig Kappa, Immunoglobulin E, CD8α, TVB2, CD52, LNGFR signal peptide.

7. The recombinant polypeptide of claim 5 , wherein the signal peptide comprises an amino acid sequence having at least 95% identity with any one of SEQ ID NOs: 2, 4, 6, 8, 10, 12, and 14.

8. The recombinant polypeptide of claim 5 , wherein the signal peptide comprises the amino acid sequence of any one of SEQ ID NOs: 2, 4, 6, 8, 10, 12, and 14.

9. The recombinant polypeptide of claim 5 , wherein the signal peptide comprises an amino acid sequence having at least 95% identity with SEQ ID NO: 4.

10. The recombinant polypeptide of claim 5 , wherein the signal peptide comprises an amino acid sequence having at least 99% identity with SEQ ID NO: 4.

11. The recombinant polypeptide of claim 5 , wherein the signal peptide comprises the amino acid sequence of SEQ ID NO: 4.

12. The recombinant polypeptide of claim 1 , comprising an amino acid sequence having at least 90% identity with any one of SEQ ID NOs: 73, 77, and 81.

13. The recombinant polypeptide of claim 1 , comprising an amino acid sequence having at least 95% identity with any one of SEQ ID NOs: 73, 77, and 81.

14. The recombinant polypeptide of claim 1 , comprising an amino acid sequence having at least 99% identity with any one of SEQ ID NOs: 73, 77, and 81.

15. The recombinant polypeptide of claim 1 , comprising an amino acid sequence of any one of SEQ ID NOs: 73, 77, and 81.

Assignments (3)
PATENT SECURITY AGREEMENT Recorded Sep 3, 2025
From: PRECIGEN, INC.; GENVEC LLC; PRECIGEN ACTOBIO, INC.; EXEMPLAR GENETICS, LLC
To: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
Reel/Frame 072828/0564 →
CHANGE OF NAME Recorded Jun 11, 2021
From: INTREXON CORPORATION
To: PRECIGEN, INC.
Reel/Frame 056556/0680 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2021
From: SHAH, RUTUL R.; EMTAGE, PETER; YARLAGADDA, RAMYA
To: INTREXON CORPORATION
Reel/Frame 056186/0001 →
Continuity (3)
Continuation 16001759 · Jun 6, 2018
Provisional Application 62516639 · Jun 7, 2017
Related Publication 20210324350A1 · Oct 21, 2021